|
PROJECTS
which have received research grants 2007
|
| |
|
|
|
|
Name |
Place |
Project title |
SEK |
| Per-Ola Andersson |
Gothenburg |
Chronic lymphatic leukemia (CLL): Tumour immunology and immunotherapy |
60.000 |
|
Tommy Andersson |
Malmö |
Cell adhesion - a clinical verified target for inhibition of metastases of epithelial tumours. |
150.000 |
| Ulrika Andréasson |
Lund |
Gene expression analyses of malignant B cell lymphomas |
15.000 |
| Håkan Axelson |
Malmö |
Novel cancer treatment strategies based on inhibition of Notch signalling |
100.000 |
| Bo Baldetorp |
Lund |
Anti-tumour treatment with internalizing monoclonal antibodies |
60.000 |
| Mattias Belting |
Lund |
Targeted anti-angiogenesis cancer treatment |
100.000 |
| Johan Bengzon |
Lund |
Development of stem cells as vehicles for brain tumor therapy |
60.000 |
| Anders Bjartell |
Malmö |
Predictive prostate cancer biomarkers |
150.000 |
| Åke Borg |
Lund |
Classification of familiar and sporadic breast cancer |
200.000 |
| Charlotte Bratt |
Lund |
Tumour markers and cancer |
60.000 |
| Ann Brun |
Lund |
Expansion of hemotopoietic stem cell |
60.000 |
| Eva Brun |
Lund |
Positron emission tomography (PET) and cervical cancer |
60.000 |
| Christina Carlsson |
Lund |
Hereditary cancer – psychosocial follow-up |
60.000 |
| Bertil Casslén |
Lund |
Gynecological cancer - early diagnostics |
60.000 |
| Eva Cavallin-Ståhl |
Lund |
Sweden, Norway Testicular Cancer (SWENOTECA) cooperation group. Follow-up of new treatments |
110.000 |
| Anna Darabi |
Lund |
Immunotherapy of murine gliomas |
60.000 |
| Kristina Drott |
Lund |
Targeted anti-leukemia treatment (p53 target gene TRIM22) |
60.000 |
| Jacob Engellau |
Lund |
Sarcomas: Improved diagnostics and prognostics |
75.000 |
| Elisabet Englund |
Lund |
Classification of glioblastomas for improved diagnostics and prognostics |
75.000 |
| Magnus Essand |
Uppsala |
Oncolytic adenoviral therapy of prostate cancer |
109.457 |
| Mårten Fernö |
Lund |
Breast cancer: Radioresistance and local recurrencies |
150.000 |
| Thoas Fioretos |
Malmö |
Genomic characterisation and functional studies on leukemia associated genetic aberrations |
150.000 |
| David Gisselsson |
Lund |
Studies on mechanism for chromosomal instability in tumours: potentials for prognostics and therapy |
100.000 |
| Aleksander Giwercman |
Malmö |
Genetic polymorphisms and cancer testis |
150.000 |
| Yvonne Giwercman |
Malmö |
Prostate cancer: importance of genetic variants |
100.000 |
| Urban Gullberg |
Lund |
Studies on cell differentiation in leukemia |
60.000 |
| Britta Halvarsson |
Helsingborg |
Colo-rectal cancer:
tumour biology and improved histo-pathology diagnostics
|
60.000 |
| Ingrid Hedenfalk |
Lund |
DNA profiles in primary breast cancer |
60.000 |
| Rebecka Hellsten |
Malmö |
Treatment of prostate cancer: development of STAT3 inhibitors |
60.000 |
| Anne Hultquist |
Lund |
Hematopoietic stem cell function |
60.000 |
| Mattias Höglund |
Lund |
Studies on genomic changes in bladder carcinomas |
100.000 |
| Mats Jerkeman |
Lund |
Prognostic factors in aggressive B cell lymphomas |
60.000 |
| Helena Jernström |
Lund |
Medical treatment of breast cancer. Prognostic importance of gene polymorphism for drug metabolism |
60.000 |
| Karin Jirström |
Malmö |
Breast cancer: tissue array analyses of risk factors |
100.000 |
| Jan Johansson |
Lund |
Genetic markers in gastroesophageal tumours |
60.000 |
| Martin Eugén Johansson |
Malmö |
Clear cell renal cancer: studies on VHL non-dependent tumour progression |
60.000 |
| Anders Johnsson |
Lund |
EGFR inhibition as radiosensitizer |
60.000 |
| Göran Jönsson |
Lund |
Molecular characterisation of malignant melanomas |
60.000 |
| Göran Landberg |
Malmö |
Tamoxifen response in breast cancer |
150.000 |
| Jenny Liao Persson |
Malmö |
Cancer stem cells in leukemia and prostate cancer |
100.000 |
| Annika Lindblom |
Stockholm |
Risk factors in colo-rectal cancer |
60.000 |
| Michael Ljungberg |
Lund |
Physics and dosimetry in systemic radiotherapy |
60.000 |
| Anders Malmström |
Lund |
The role of proteoglycans in squamous cell cancer. |
60.000 |
| Mef Nilbert |
Lund |
Development of hereditary colo-rectal cancer. How? |
200.000 |
| Ulrike Nuber |
Lund |
Glioma stem cells |
75.000 |
| Ioannis Panagopoulos |
Lund |
Molecular-genetic studies on soft tissue tumours and leukemia |
75.000 |
| Helen Pettersson |
Malmö |
Tumour multidrug resistance with focus on arsenic trioxide effects |
70.000 |
| Sven Påhlman |
Malmö |
Tumour aggressiveness and hypoxia |
150.000 |
| Thomas Relander |
Lund |
Genetic aberrations in T cell lymphomas |
60.000 |
| Karin Rennstam |
Lund |
Epigenetics and microenvironmental influence in breast cancer |
60.000 |
| Lars Rönnstrand |
Malmö |
Investigation of alterations in the c-Kit signal transduction machinery |
100.000 |
| Birgitta Sander |
Stockholm |
Mantle cell lymphomas - pathogenesis and therapy targets |
60.000 |
| Stefan Scheding |
Lund |
Mesenchymal stem cells (MSC) from bone marrow and osteosarcomas |
100.000 |
| Peter Siesjö |
Lund |
Dendritic cell-based therapy for the treatment of experimental brain tumors |
60.000 |
| Ewa Sitnicka |
Lund |
Flt3 in normal and malignant hematopoiesis |
100.000 |
| Anita Sjölander |
Malmö |
Inflammation-induced colon cancer |
60.000 |
| Sven-Erik Strand |
Lund |
Systemic radiotherapy – optimizing therapy |
150.000 |
| Jan Tennvall |
Lund |
Targeted radioimmunotherapy of cancer |
150.000 |
| Johan Wennerberg |
Lund |
Effects of erythropoitin (EPO) and other cytokines on tumour growth after surgical trauma |
100.000 |
| |
|
|
|
|
Total 2007: 59 grants – SEK 5.194.457
Total amount of contributions from the public 2006 – SEK 429.457 - shared by 4 researchers:
3 grants awarded to prostate cancer, total SEK 359.457 and one grant awarded to lung cancer, SEK 70.000.
These four research projects are marked with extra bold type in the list.
|
